This study aims to evaluate the immunogenicity of the drug by measuring anti-drug antibody (ADA) formation and titers. The presence of ADAs will be assesses to determine their potential impact on the drug's efficacy and safety.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Annualized rate of clinically significant asthma exacerbations
Timeframe: 12 month
Number of participants experiencing at least one asthma exacerbation
Timeframe: 12 month